Characterization and Management of Cytopenias after Imetelstat Treatment in the IMerge Phase 3 Trial of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

被引：0

作者：

Zeidan, Amer M. ^{[1
,2
]}

Savona, Michael R. ^{[3
]}

Madanat, Yazan F. ^{[4
]}

Fenaux, Pierre ^{[5
]}

Komrokji, Rami S. ^{[6
]}

Jonasova, Anna ^{[7
]}

Illmer, Thomas

Sun, Libo ^{[8
]}

Berry, Tymara ^{[8
]}

Feller, Faye M. ^{[8
]}

Navada, Shyamala ^{[8
]}

Santini, Valeria ^{[9
,10
]}

Platzbecker, Uwe ^{[11
]}

机构：

[1] Yale Univ, Yale Sch Med, New Haven, CT USA

[2] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[3] Vanderbilt Univ, Med Ctr, Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[4] UT Southwestern Med Ctr, Harold C Simmons Comprehens Canc Ctr, Dallas, TX USA

[5] Univ Paris 07, Hop St Louis, Paris, France

[6] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[7] Gen Hosp, Prague, Czech Republic

[8] Geron Corp, Parsippany, NJ USA

[9] Azienda Osped Univ Careggi, MDS UNIT, DMSC, Florence, Italy

[10] Univ Florence, Florence, Italy

[11] Leipzig Univ Hosp, Cellular Therapy & Hemostaseol, Leipzig, Germany

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-180962

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[1] Effect of Luspatercept on Biomarkers of Erythropoiesis in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Medalist Trial
Platzbecker, Uwe
Zhu, Yiming
Ha, Xianwei
Risueno, Alberto
Chan, Esther
Zhang, George
Dunshee, Diana R.
Acar, Melih
Shetty, Jeevan K.
Ito, Rodrigo
MacBeth, Kyle
Santini, Valeria
Garbowski, Maciej W.
Fenaux, Pierre
Schwickart, Martin
BLOOD, 2020, 136
[2] Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
Fenaux, Pierre
Santini, Valeria
Mufti, Ghulam J.
Diez-Campelo, Maria
Finelli, Carlo
Sekeres, Mikkael A.
Quesnel, Bruno
Beyne-Rauzy, Odile
Garcia-Manero, Guillermo
Komrokji, Rami S.
Buckstein, Rena
Voso, Maria Teresa
Selleslag, Dominik
DeZern, Amy E.
Greenberg, Peter L.
Zeidan, Amer M.
Ades, Lionel
Verma, Amit
Savona, Michael R.
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Rampersad, Anita
Sinsimer, Daniel
Morison, Jessica
Louis, Chrystal
Linde, Peter G.
Platzbecker, Uwe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S317 - S317
[3] Impact of Mutational Status on Clinical Response to Imetelstat in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Phase 3 Study
Santini, Valeria
Zeidan, Amer M.
Fenaux, Pierre
Madanat, Yazan F.
Berry, Tymara
Feller, Faye M.
Sun, Libo
Xia, Qi
Wan, Ying
Huang, Fei
Savona, Michael R.
Platzbecker, Uwe
BLOOD, 2023, 142
[4] RATIONALE FOR THERAPY DISCONTINUATION IN PATIENTS WITH LOWER-RISK TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES (LR-MDS)
Gerds, A. T.
Gupta, S.
Sekeres, M. A.
Nazha, A.
Carraway, H. E.
Hawthorne, S.
King-Concialdi, K.
McGuire, M.
LEUKEMIA RESEARCH, 2017, 55 : S140 - S141
[5] Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Santini, Valeria
Komrokji, Rami S.
Sekeres, Mikkael A.
Savona, Michael Robert
Fenaux, Pierre
Madanat, Yazan F.
Oliva, Esther
Buckstein, Rena
Jonasova, Anna
Germing, Ulrich
Mittelman, Moshe
Thepot, Sylvain
Riggs, Jennifer
Dougherty, Souria
Berry, Tymara
Navada, Shyamala
Xia, Qi
Sun, Libo
Zeidan, Amer M.
Platzbecker, Uwe
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S386 - S387
[6] Assessment of Dose-Dependent Response to Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial
Platzbecker, Uwe
Fenaux, Pierre
Mufti, Ghulam J.
Garcia-Manero, Guillermo
Komrokji, Rami S.
Buckstein, Rena
Diez-Campelo, Maria
Finelli, Carlo
Sekeres, Mikkael A.
Selleslag, Dominik
DeZern, Amy E.
Quesnel, Bruno
Beyne-Rauzy, Odile
Voso, Maria Teresa
Greenberg, Peter L.
Zeidan, Amer M.
Ades, Lionel
Verma, Amit
Savona, Michael R.
Laadem, Abderrahmane
Ito, Rodrigo
Zhang, Jennie
Rampersad, Anita
Morison, Jessica
Louis, Chrystal
Linde, Peter G.
Santini, Valeria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S318
[7] Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study
Zeidan, Amer M.
Garcia-Manero, Guillermo
DeZern, Amy E.
Fenaux, Pierre
Greenberg, Peter L.
Savona, Michael R.
Jurcic, Joseph G.
Verma, Amit
Mufti, Ghulam J.
Buckstein, Rena
Santini, Valeria
Laadem, Abderrahmane
Zhang, Jennie
Rampersad, Anita
Sinsimer, Daniel
Louis, Chrystal U.
Linde, Peter G.
Platzbecker, Uwe
Sekeres, Mikkael A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S318 - S319
[8] Assessment of dose-dependent response to luspatercept in patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the phase 3 MEDALIST trial
Platzbecker, U.
Germing, U.
Goetze, K.
Heuser, M.
Thol, F.
Fenaux, P.
Komrokji, R. S.
Laadem, A.
Ito, R.
Zhang, J.
Rampersad, A.
Morison, J.
Louis, C. U.
Giagounidis, A.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 171 - 171
[9] Long-term utilization and benefit of luspatercept in patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS) from the MEDALIST trial.
Fenaux, Pierre
Santini, Valeria
Komrokji, Rami S.
Zeidan, Amer Methqal
Garcia-Manero, Guillermo
Buckstein, Rena
Miteva, Dimana
Keeperman, Karen
Holot, Natalia
Zhang, Jennie
Hughes, Christina
Rosettani, Barbara
Yucel, Aylin
Platzbecker, Uwe
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] Improvement of Patient-Reported Outcomes Among Heavily Pretreated Patients with Lower-Risk Myelodysplastic Syndromes and High Transfusion Burden Treated with Imetelstat on the IMerge Phase 3 Trial
Sekeres, Mikkael A.
Diez-Campelo, Maria
Zeidan, Amer M.
Platzbecker, Uwe
Regnault, Antoine
Creel, Kristin
Sengupta, Nishan
Wan, Ying
Sun, Libo
Xia, Qi
Berry, Tymara
Dougherty, Souria
Shah, Sheetal
Navada, Shyamala
Santini, Valeria
Valcarcel, David
BLOOD, 2023, 142

← 1 2 3 4 5 →